# Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income Statement

- Company: Indivior Pharmaceuticals, Inc. (INDV)
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001628280-26-068013
- Page: https://plicit.ai/financials/indv/fy2026-q3-income-statement
- Chart image: https://plicit.ai/charts/indv-fy2026-q3-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Geography

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 356,000,000 US dollars
- **Cost of sales**: 51,000,000 US dollars
- **Gross profit**: 305,000,000 US dollars
- **Total operating expenses**: 125,000,000 US dollars
- **Operating income**: 180,000,000 US dollars
- **Other income (expense), net (calculated)**: 2,000,000 US dollars
- **Income before income taxes**: 182,000,000 US dollars
- **Income tax expense (benefit)**: 45,000,000 US dollars
- **Net income**: 137,000,000 US dollars
- **Reportable Segment - UNITED STATES**: 307,000,000 US dollars
- **Reportable Segment - Rest of World**: 48,000,000 US dollars
- **Undisclosed (calculated)**: 1,000,000 US dollars
- **Selling, general and administrative**: 119,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
- **Research and development**: 5,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
